Cambridge Healthtech Institute’s 2nd Annual 

Protein & Antibody Engineering 
Innovative Engineering * Novel Scaffolds * Bispecific Antibodies

March 31-April 1, 2015


The field of protein engineering is at an exciting point in its development, with new generations of protein and antibody formats entering the market, improved understanding of structure-function relationships, and creative engineering that promises to optimize molecules with improved biophysical properties.

The Protein & Antibody Engineering conference presents the state of the art in strategies and techniques to enhance antibody binding and specificity, design of novel scaffolds with increased potency, as well as new and enhanced applications for bispecific antibodies.


Antibody Development Strategies in Today’s China

Chengbin Wu, Ph.D., President, Research & Development and CSO, Shanghai C P Guojian Pharmaceutical Co. Ltd., PR China

ADC: Is It Time to Rethink Some Preconceptions?

Jaume Pons, Ph.D., Senior Vice President and CSO, Rinat


Antibody Engineering for Better in vivo Efficacy

Weidong Jiang, Ph.D., CSO, Henlius Biopharmaceuticals, Inc.

In vitro and in vivo Study of pH-Dependent Antigen Binding Antibody with Increased FcgammaRIIB Binding

Yuji Hori, Ph.D., Research Scientist, Chugai Pharmaceutical, Japan


Anticalins: Versatile Binding Proteins based on a Flexible Natural Scaffold

Arne Skerra, Ph.D., Professor, Technische Universität München; Founder, Pieris AG, Germany

ADAPT - A Novel Scaffold Protein for Radionuclide Molecular Imaging

Johan Nilvebrant, Ph.D., Postdoctoral Researcher, The Donnelly Centre, Center for Cellular and Biomolecular Research, University of Toronto, Canada

Exceptionally Potent and Broad Inhibitors of HIV-1 based on Antibody Domains and One Domain Soluble CD4 Multivalent Fusion Proteins

Dimiter Dimitrov, Ph.D., Senior Investigator, NCI, National Institutes of Health

Cross-Neutralizing Single-Domain Antibodies to Pandemic Influenza

Simon E Hufton, Ph.D., Principal Scientist, Biotherapeutics, National Institute for Biological Standards and Control (NIBSC)


Antibody Engineering Strategies for the Production of Bispecific Heterodimeric IgG in Mammalian Cells

Wei Yan, Ph.D., Director, Research, Therapeutic Discovery, Amgen, Inc.

Design and Development of Next-Generation Bispecific Antibodies with Good Drug-Like Properties (DLP)

Jinming Gu, Ph.D., Senior Scientist, Global Biologics, Abbvie, Inc.

Bispecific Antibody Formats Tailored for Specific Applications

Jochen Kruip, Ph.D., Department Head, BioInnovation Novel Therapeutic Protein Formats, Sanofi

Therapeutic Applications of DART Proteins – What’s Next?

Syd Johnson, Ph.D., Vice President, Antibody Engineering, MacroGenics, Inc.

Targeted Delivery of Nanomedicines Using Bispecific Antibodies

Stephen Mahler, Ph.D., Professor, Australian Institute for Bioengineering and Nanotechnology, University of Queensland

The Development of Antibody-Based Therapeutics for the Treatment of Emerging Infectious Diseases

Tianlei Ying, Ph.D., Head, Antibody Engineering and Drug Discovery Group, School of Basic Medical Science, Fudan University

Clinical Development of Tanibirumab and Its Bispecific Antibody, DIG-KT

Jin-San Yoo, Ph.D., President & CEO, PharmAbcine, Inc., Korea

For questions about the meeting, please contact: 

Mimi Langley 郭咪咪
Sr. Conference Director
Cambridge Healthtech Institute
Phone: +1 816-472-0701

For partnering & sponsorship information, please contact: 

Companies A-K 

Jason Gerardi
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Fax: 781-972-5470

Companies L-Z 

Carol Dinerstein
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5471
Fax: 781-972-5470

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 

Register Now 

Download 2014 Brochure
2014 ABA Brochure Icon

Premier Sponsor
Protein Simple 

View All Sponsors > 

View Media Partners > 

Promote your company’s latest technology and/or solution at PEGS CHINA. A limited number of agenda presentations (as part of a sponsorship package), exhibit space, branding, and promotional opportunities are available.

Track 1

Protein Engineering 

Track 2

Phage & Yeast Display 

Track 3

Antibody-Drug Conjugates 

Track 4

Characterization of Biotherapeutics